Metachromatic Leukodystrophy

- Cell Therapy Approaches

Metachromatic leukodystrophy (MLD) is a lysosomal storage disease caused by a deficiency of the enzyme arylsulfatase A, which results in accumulation of sphingolipids, eventually destroying the myelin sheath in the nervous system.

Cell Therapy Approaches

In patients with enzymatic abnormalities and metabolic storage disorders, cell therapy enables synthesis of normal functional enzymes that can circulate and improve cellular functions of the native tissues. Cell therapy based upon bone marrow and bone marrow-derived stem cell transplantation can potentially reduce or halt disease progression in the central nervous system.

This site does not provide medical advice and is for research use only

Welcome to
LifeMap Discovery

Watch the introductory video to learn more about our database of embryonic development for stem cell research and regenerative medicine

Metachromatic Leukodystrophy

- Cell Therapy Approaches

Cell Therapy Approaches

Cell Therapies for the treatment of

Modeling of

Affected or Therapy-targeted Cells/Compartments for

Literature related to

Welcome to LifeMap Discovery

Watch the introductory video to learn more about our database of embryonic development for stem cell research and regenerative medicine

Metachromatic Leukodystrophy - Cell Therapy Approaches

Cell Therapy Approaches

Cell Therapies for the treatment of

Modeling of

Affected or Therapy-targeted Cells/Compartments for

Literature related to

Welcome to
LifeMap Discovery

Metachromatic Leukodystrophy

- Cell Therapy Approaches